As TFAP2A loss leads to compromised hypoxic response with decreased expression of glycolytic and EMT‐related genes, targeting the TFAP2A/HIF interaction may offer a potent therapeutic approach for shutting down distinct routes of the HIF response pathway, which would in turn cause cancer cell death within hypoxic tumors. This evidence concerns the gene TFAP2A and cancer.